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NONLINEAR DYNAMICS AND CONTROL IN A TUMOR-IMMUNE SYSTEM 
YU XUAN 
ABSTRACT 
Advances in modeling tumor-immune dynamics and therapies offer deeper 
understandings of the mechanism of tumor evolution in the interdisciplinary field of 
mathematics and immune-oncology. The main mathematical models are constructed in 
terms of ordinary differential equations (ODEs) or partial differential equations (PDEs) 
and analyzed through tools such as Poincaré map, simulation, or numerical bifurcation 
analysis to understand the system properties. These models succeed in characterizing 
essential features of tumor behaviors including periodic bursts and the existence of 
latency. In relationship to practice, these models are also applied to estimate the 
feasibility and efficacy of treatments ranging from traditional chemotherapy to 
immunotherapy (ACI). 
In recent literature, there have been applications of control methods such as 
optimal control, hybrid automata, and feedback linearization-based tracking control with 
almost disturbance decoupling in the studies of tumor-immune systems. This thesis 
presents an attempt to apply the bifurcation control method with washout filters in tumor 
treatments. 
This thesis research investigates the dynamics and controlling of the tumor-
immune response of immunotherapies, mainly the Adoptive Cell Immunotherapy (ACI) 
and Interleukin-2 (IL-2). The first part of the thesis presents the nonlinear dynamics of 
the classic nonlinear ODE tumor-immune model given by Denise Kirschner and John 
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Carl Panetta in 1998. This model concentrates on the nonlinear phenomena of the tumor-
immune system under immunotherapies, primarily the bifurcation phenomenon along 
with the antigenicity of effector cells. Bifurcation phenomena refer to the qualitative 
changes in system dynamics due to quasi-static changes in system parameters. 
Antigenicity refers to a capability to distinguish tumor cells from healthy cells. The 
Kirschner-Panetta model captures a saddle-node bifurcation and a Hopf bifurcation of the 
tumor-immune response, which separates the tumor evolution into three stages, the 
“dangerous equilibrium”, the periodic recurrence, and the “safe equilibrium”.  
The second part applies and analyzes several control strategies on the 
immunotherapies based on the KP model in order to eradicate tumors or inhibit tumor 
growths. The first section studies the combination immunotherapy of ACI and IL-2 as an 
open-loop control system based on Kirschner’s work, which generates a locally 
asymptotically stable equilibrium. In the second section, this thesis provides a new idea 
of treatment in the tumor-immune system, that is a closed-loop control strategy taking 
advantage of its bifurcation structure by applying dynamic feedback control with a 
washout filter of ACI or IL-2. Bifurcation control moves the Hopf bifurcation point 
without changing the equilibrium structure as the bifurcation parameter varies. In this 
tumor-immune case, the linear dynamic feedback control with a washout filter of ACI 
could either extend the “safe equilibrium” region or reduce the amplitude of the tumor 
population at the stage of tumor recurrence. In addition, other bifurcation amplitude 
controls of either ACI or IL-2 are attempted to reduce the amplitudes of periodic orbits of 
the tumor immune system but without obvious effects.   
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CHAPTER ONE  INTRODUCTION 
Cancer is one of the leading fatal diseases. Though surgical resection, 
chemotherapy, and radiotherapy have played a significant role in tumor or cancer 
treatment in clinical, there is an urgent need for more effective therapies against 
neoplasms. As a result, immunotherapy has greatly progressed in recent decades. In the 
1970s, there was considerable enthusiasm for immunotherapeutic approaches that apply 
nonspecific substances to stimulate immune systems against tumor growth, but those 
approaches were abandoned soon [25]. Since the 1980s, an alternate method, the so-
called passive or adoptive immunotherapy, has made considerable headways [2]-[12]. 
The passive immunotherapy refers to a systematic transfer of the substances or cells that 
already own anti-tumor abilities. In this thesis, immunotherapy refers in particular to 
passive immunotherapy.  
The immunotherapy usually includes cytokines and adoptive cellular 
immunotherapies (ACI). According to [15], “Cytokines are protein hormones that 
mediate both natural and specific immunity. They are produced mainly by activated T 
cells (lymphocytes) during cellular-mediated immunity. Interleukin-2 (IL-2) is the main 
cytokine responsible for lymphocyte activation, growth, and differentiation.” ACI is an 
immunological treatment that implants into tumor-bearing hosts the immune cells 
(effector cells) whose anti-tumor features have been activated in vitro. Lymphokine-
activated killer cell (LAK) therapy and tumor infiltrating lymphocyte (TIL) therapy are 
two principal approaches to achieve ACI.   
In the interdisciplinary field of mathematics and immunology, advances in 
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modeling tumor-immune dynamics and therapies offer a deeper understanding of the 
mechanism of tumor evolution. The main mathematical models are constructed in terms 
of ordinary differential equations (ODEs) or partial differential equations (PDEs) [1] and 
analyzed through tools such as Poincaré map, simulation, or numerical bifurcation 
analysis to understand the system properties. ODE models describe the temporal 
dynamics of tumor-immune interaction at the cellular or molecular level, and PDE 
models involve more factors such as spatial effects. These models succeed in 
characterizing essential features of tumor behaviors, such as periodic bursts and the 
existence of latency. In relationship to practice, these models are also applied to estimate 
the feasibility and efficacy of treatments ranging from traditional chemotherapy and 
radiotherapy to immunotherapy (ACI). This thesis focuses on a specific ODE model. 
Potentially lethal tumor cells might keep in a “safe” state that the population 
persists to be harmlessly small for a host over a long period; but the small population 
might boom all of a sudden in the lack of immunological surveillance. Kuznetsov etc. 
[14] relate these special phenomena of “dormant state” and “sneaking through” with 
nonlinear dynamics via an ODE model. This model quantitatively describes the 
interaction between two central populations, the effector cells, and tumor cells. This 
model was shown to possess stable spirals, but its dynamics is not rich enough since the 
Dulac-Bendixson criterion proves that there does not exist stable closed orbits.  
Kirschner and Panetta [15] furthered Kuznetsov’s model by incorporating other 
mathematical modellings of tumor-immune interactions [16][17][18][19]. This thesis is 
based on the Kirschner and Panetta model (KP model). They constructed a three- 
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dimensional ODE model of tumor-immune interactions under immunotherapy. 
Comparing to Kuznetsov’s model that focuses on the anti-tumor mechanism of immune 
systems, the KP model tends to guide oncotherapy, especially the immunotherapy, by 
introducing treatment terms of adoptive cellular immunotherapy (ACI) and Interleukin-2 
(IL-2). The KP model captures a periodic response of tumor-immune which corresponds 
to the neoplasm recurrence in clinical. They also indicate that a combination treatment of 
ACI and IL-2 works better than single treatments with either ACI or IL-2. Only the 
combination treatment could eliminate tumor cells.  
The classic KP model is simple enough to motivate further research work of 
modeling tumor-immune systems and applications of mathematical control [20]. Phillis 
etc. [21] develop a mixed-treatment model combining immunotherapy and 
chemotherapy, based on which Rihan etc. [22] have also studied an optimal control 
problem with delay in the effect of effector cells. Mallet etc. [23] construct a hybrid 
cellular automaton based on the temporary results from the KP model. Chien etc. [24] 
apply feedback linearization with almost disturbance decoupling control directly to the 
KP model, and the method assumes that all state variables are measurable using a 
programmable research micro-pump and computer, such as the Cellometer Auto T4 Cell 
Counter.  
In recent years, there has also been a growing body of research on control of 
nonlinear dynamical systems exhibiting bifurcation phenomena. The objective of the 
bifurcation control is to modify the system behaviors by relocating bifurcation points or 
changing the stability properties of bifurcation branches. Bifurcation control has been 
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applied to a wide range of applications such as voltage collapse in power systems, 
rotating stall and surge in compression systems, cardiac dynamics with arrhythmias, to 
name a few [26]. Based on a transformed Lorenz equation,  the work in [27] shows 
dynamic bifurcation control with washout filters can change the location and stabilize 
Hopf bifurcations without changing the equilibrium structure of the system.  
This thesis research investigates the dynamics and controlling of the tumor-
immune response of immunotherapies, mainly the ACI and the IL-2. The first part of the 
thesis presents the nonlinear dynamics of the classic nonlinear ODE tumor-immune 
model given by Denise Kirschner and John Carl Panetta in 1998. This model concentrates 
on the nonlinear phenomena of the tumor-immune system under immunotherapies, 
primarily the bifurcation phenomenon along with the antigenicity of effector cells. 
Bifurcation phenomena refer to the qualitative changes in system dynamics due to quasi-
static changes in system parameters. Antigenicity refers to a capability to distinguish 
tumor cells from healthy cells. The KP model captures a saddle-node bifurcation and a 
Hopf bifurcation of the tumor-immune response, which separates the tumor evolution 
into three stages, the “dangerous equilibrium”, the periodic recurrence, and the “safe 
equilibrium”.  
The second part applies and analyzes several control strategies on the 
immunotherapies based on the KP model in order to eradicate tumors or inhibit tumor 
growths. The first section studies the combination immunotherapy of ACI and IL-2 as an 
open-loop control system based on Kirschner’s work, which generates a locally 
asymptotically stable equilibrium. In the second section, this thesis provides a new idea 
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of treatment in the tumor-immune system, that is a closed-loop control strategy taking 
advantage of its bifurcation structure by applying dynamic feedback control with a 
washout filter of ACI or IL-2. Bifurcation control moves the Hopf bifurcation point 
without changing the equilibrium structure as the bifurcation parameter varies. In this 
tumor-immune case, the linear dynamic feedback control with a washout filter of ACI 
could either extend the “safe equilibrium” region or reduce the amplitude of the tumor 
population at the stage of tumor recurrence. Furthermore, other bifurcation amplitude 
controls of either ACI or IL-2 are attempted to reduce the amplitudes of periodic orbits of 
the tumor immune system but without obvious effects. 
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CHAPTER TWO  NONLINEAR ANALYSIS OF THE TUMOR-IMMUNE 
INTERACTIONS 
2.1  Preliminaries of Bifurcation Theory 
Phenomena of nonlinear systems can be rich and complex, and the phenomena 
might become more intricate when parameters change in corresponding systems. To 
systematically understand the nonlinear dynamics along with varying parameters, we can 
classify the complex nonlinear dynamics into distinct patterns according to the existence 
and stability properties of equilibrium points, period orbits or other invariant subsets. 
Bifurcation refers to the critical situation that those essential properties of a nonlinear 
system undergo qualitative transformations with quasi-static changes of system 
parameters. These system parameters are defined as bifurcation parameters, and the 
parameter values at which critical changes occur are called bifurcation points [13]. 
Bifurcation diagram is a graphically descriptive tool for bifurcation analysis which 
structurally depicts the relationship between the essential nonlinear properties and 
bifurcation parameters. 
Consider a one-parameter finite dimensional system 
?̇? = 𝒇(𝒙, 𝑐), (2.1) 
where 𝒙 ∈ ℝ𝑛 is the state vector, 𝑐 ∈ ℝ is the bifurcation parameter, and 𝒇: ℝ𝑛+1 → ℝ𝑛 
is the smooth vector field. Without losing any generality, consider the situation that the 
origin 𝒙 = 𝟎 is an equilibrium point and the Jacobian matrix 𝐽 ≜
𝜕𝒇
𝜕𝒙
|
𝒙=𝟎,𝑐=0
 owns 
eigenvalues with zero real parts. Suppose that the origin loses stability, i.e., any the 
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Jacobian eigenvalue crosses the complex axis, when 𝑐 changes sign, then a bifurcation 
point occurs at 𝑐 = 0. 
Figure 2.1 summaries the nondegenerate bifurcations. Saddle-node bifurcation (a) 
results from a collision between a stable node equilibrium point and a saddle equilibrium 
point. As the bifurcation parameter pass through the bifurcation point, both stable 
equilibrium branch and unstable equilibrium branch generate together. Transcritical 
bifurcation (b) refers to the crossing point of two equilibrium branches. The equilibrium 
branches change their stability properties after an intersection. Pitchfork bifurcation (c 
and d) combines generations of new branches and changes of stability. Single equilibrium 
branch changes its stability property when traversing the bifurcation point, as well as two 
equilibrium branches that remain the original stability arise above and below. These 
bifurcations are collectively called stationary bifurcation where only equilibrium points 
take place. Hopf bifurcation (e and f) looks similar to Pitchfork bifurcation. The 
difference is that two branches of limit cycle arise here instead of two equilibrium 
branches in the pitchfork bifurcation. Besides, supercritical bifurcation (c and e) and 
subcritical bifurcation (d and f) classify the bifurcation phenomena into safe and 
dangerous cases. The dynamics of supercritical case transfer smoothly, while those of 
subcritical case, transcritical and saddle-node always result in a system hysteresis or state 
jumps due to the disappearance of stable branches [13].  
In this thesis research, both saddle-node bifurcation and Hopf bifurcation are 
discovered and discussed. Therefore, it is necessary to present the mathematical 
description of both stationary bifurcation and Hopf bifurcation. 
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Figure 2.1 Nondegenerate bifurcation diagrams (solid line: stable equilibrium,  
dash line: unstable equilibrium, circle: bifurcation points). 
 
2.1.1  Stationary Bifurcation 
Transform the system, equation (2.1), into a linearized form 
?̇? = A(𝑐)𝒙 + 𝒇(𝒙;  𝒄) (2.2) 
where 𝒇 ∈ 𝐶𝑘(ℝ𝑛) with k ≥ 3, 𝒇(𝒙𝟎;  𝒄) = 𝟎， 
𝛛𝒇
𝛛𝒙
(𝒙𝟎;  𝒄) = 𝟎 for all sufficiently small 
|𝑐 − 𝑐0|, and 𝑐0 is the value of 𝑐 at the bifurcation point.  
A stationary bifurcation is guaranteed to occur when a single real eigenvalue goes 
from being negative to being positive as 𝑐 passes through the value 𝑐0. More precisely, 
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the origin of the system (2.1) undergoes a stationary bifurcation at the critical parameter 
value 𝑐 = 0 if the following hypothesis hold [35][36]: 
1. Vector field 𝒇 in the system (2.1) is sufficiently smooth in 𝒙, 𝑐, and 
𝒇(𝒙𝟎;  𝒄) = 𝟎 for all 𝑐 in a neighborhood of 0. The Jacobian A(𝑐) ≜
𝛛𝒇
𝛛𝒙
(𝟎, 𝒄) 
possesses a simple real eigenvalue λ(𝑐) such that λ(0) = 0 and λ′(0) ≠ 0; 
2. All eigenvalues of the critical Jacobian A(𝑐) besides 0 have negative real 
parts. 
2.1.2  Hopf Bifurcation 
Assume that the linear part A(𝑐) in equation (2.2) at the origin has a pair of 
eigenvalues λ1,2(𝑐) = α(𝑐) ± iω(𝑐) with α(𝑐0) = 0 and ω(𝑐0) ≠ 0. Furthermore, 
suppose that the pair of eigenvalues cross the imaginary axis with nonzero speed, i.e., 
∂𝛼
∂𝑐
(𝑐0) ≠ 0, (2.3) 
which is known as the transversality condition for the crossing of the eigenloci at the 
imaginary axis. Then in any neighborhood 𝑈 of the point 𝑥0 and for any given ε > 0, 
there is a |𝑐̅ − 𝑐0| < 𝜀 such that the differential equation (2.2) has a nontrivial periodic 
orbit in 𝑈. In this case, the system is said to undergo a Hopf bifurcation at the bifurcation 
point (𝒙0, 𝑐0) [35][36]. 
2.2  Kirschner and Panetta’s Tumor-Immune Model  
This thesis research studies the dynamics and control of tumor-immune system 
under immunotherapy based on the KP model. Here is the state model:  
  
10 
𝑑𝑥1
𝑑𝑡
= 𝑐𝑥2 − 𝜇2𝑥1 +
𝑝1𝑥1𝑥3
𝑔1 + 𝑥3
+ 𝑢1 (2.4) 
𝑑𝑥2
𝑑𝑡
= 𝑟2𝑥2(1 − 𝑏𝑥2) −
𝑎𝑥1𝑥2
𝑔2 + 𝑥2
(2.5) 
𝑑𝑥3
𝑑𝑡
=
𝑝2𝑥1𝑥2
𝑔3 + 𝑥2
− 𝜇3𝑥3 + 𝑢2 (2.6) 
with the initial condition: 
𝒙(0) = [𝑥10, 𝑥20, 𝑥30]
𝑇 (2.7) 
and the output equation: 
𝑦 = 𝑥2. (2.8) 
Here the state variable 𝑥1, 𝑥2, 𝑥3 represents the population of effector cells, the 
population of tumor cells, and the concentration of IL-2, respectively; 𝑢1, 𝑢2 refers to two 
kinds of immunotherapy, ACI and IL-2.  
It is significant to understand the nonlinear terms contained in the KP model as it 
explains the mechanism of tumor-immune response through nonlinear phenomena. The 
KP model mainly contains two nonlinear terms, the logistic growth rate, and the 
Michaelis-Menten kinetics.  
The logistic function is in the form of 
𝑙(𝑣) = 𝛼(1 − 𝛽𝑣), (2.9) 
where 𝛼, 𝛽 are constants. In the dynamic equation 
𝑑𝑣
𝑑𝑡
= 𝑙(𝑣)𝑣, (2.10) 
the logistic function serves as the growth rate. Figure 2.2 shows the solution of equation 
(2.10). For 𝑣 close to zero, 𝑙(𝑣) approximates to 𝛼, then 𝑣 grows exponentially following 
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𝑒𝛼𝑡; as 𝑣 increases, 𝑙(𝑣) approaches to 0, then asymptotically 𝑣 grows to 1/𝛽. In 
biological dynamics, 1/𝛽 refers to the carrying capacity of a substance 𝑣 [1].  
 
Figure 2.2 Logistic function (𝜶𝟏 < 𝜶𝟐) 
Michaelis-Menten kinetics, a classic enzyme kinetics, relates the enzyme reaction 
rate 𝑘 to the concentration of a substance 𝑣 as  
𝑘(𝑣) =
𝛼𝑣
𝛽+𝑣
. (2.11)
Here constant 𝛼 is the upper limit of 𝑘(𝑣), and constant 𝛽 refers to the half-lifespan of 
𝑘(𝑣), i.e., the value of 𝑣 when 𝑘(𝑣) reaches half value. The Michaelis-Menten Kinetics 
is shown in Figure 2.3.  
This model simplifies and summaries the immune mechanism responding to 
tumors as an interaction among effector cells, tumor cells, and cytokine IL-2. The 
appearance of tumor cells activates the effector cells to proliferate and to secrete IL-2. IL-
2 would not eliminate tumor cells directly but work as a stimulator for the effector cells. 
Finally, effector cells could kill the identified tumor cells.  
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Figure 2.3 Michaelis-Menten Kinetics 𝒌(𝒗) 
It is challenging to account total amounts of biological components in practice. 
Instead, the model describes the evolution by the average difference in population or 
concentration within time 𝑑𝑡 in both proliferation part (positive) and death part 
(negative). According to [15], the first equation describes the rate of change for the 
effector-cell population. The defense mechanism of immune systems against tumors is 
directly activated by the tumor cells (Term1), as well as indirectly stimulated by the IL-2 
(Term 3). In Term 1, the growth rate c means the antigenicity of the tumor. Antigenicity 
describes the immunological surveillance capability of effector cells, the ability to 
distinguish tumor cells from other normal cells, and it ranges from 0 to 0.05 individually.  
The other growth term (Term 3) models the proliferation of effector cells stimulated by 
IL-2 that is produced by the effector cell itself in a both autocrine and paracrine manner. 
The Michaelis-Menten form indicates the saturated effects of the immune response with 
the highest growth rate of 𝑔1. Term 2 represents the natural death of immune cells with 
an average lifespan of 1/𝜇2 days. The final term 𝑢1 refers to the treatment that externally 
provides effector cells such as LAK or TIL cells. 
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The second equation marks the change rate in the tumor population with a logistic 
growth rate  
𝑟2(1 − 𝑏𝑥2). (2.12) 
For the tumor evolution  
𝑑𝑥2
𝑑𝑡
= 𝑟(∙)𝑥2 −
𝑎𝑥1𝑥2
𝑔2 + 𝑥2
, (2.13) 
there are three primary growth patterns differentiated by the growth rate 𝑟2(∙), the 
constant, logistic [28] and Gompertz [29][30][31] growth rate. The tumor grows 
exponentially with a constant 𝑟 or grows with limits in the latter two forms, where the 
Gompertz is smoother but much more complicated. Term 2 describes the immune 
clearance of tumor cells with a limit effect at rate 𝑎. (The Michaelis-Menten form could 
also account for the effects of a solid tumor, i.e., only a portion of the tumor mass comes 
in contact with the immune system cells.)  
Different from previous equations, Equation 3 gives the change rate of IL-2 
concentration. The source of IL-2 is the effector cells stimulated by tumors, and these 
activated effector cells secrete IL-2 with limited speed as modeled in Michaelis-Menten 
kinetics form. The next term (𝜇3) represents the natural loss rate of IL-2. Finally, 𝑢2 is a 
treatment term that represents an external input of IL-2 into the system.  
2.2.1 Parameters and Scaling 
Kirschner gives parameters in this state model based on the papers [19][14][25]. 
Noted that the units of the value given in Table 2.1 are in 𝑑𝑎𝑦𝑠−1, except for 𝑔1, 𝑔2, 𝑔3 
and 𝑏 whose units are volume.  
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𝒄 𝒂 𝒃 𝒑𝟏 𝒑𝟐 𝒓𝟐 
[𝟎, 𝟎. 𝟎𝟓] 1 1 × 10−9 0.1245 5 0.18 
𝒈𝟏 𝑔2 𝑔3 𝜇2 𝜇3  
𝟐 × 𝟏𝟎𝟕 1 × 105 1 × 103 0.03 10  
Table 2.1 parameters in the KP model 
 
This model is stiff for simulation due to the wide range of parameters. 
Appropriate scaling is necessary to carry out the numerical analysis. Normalizing the 
population of tumor cells is one option of the non-dimensional scaling. 1 𝑏⁄  refers to the 
carrying capacity of the tumor cells. As a result, all the cell number units related values 
are non-dimensionalized by 1/b. Moreover, the time units related values are non-
dimensionalized by 𝑟2 according to Kirschner’s recommendation.  
Set 
𝐸0 = 𝑇0 = 𝐼𝐿0 = 1 𝑏⁄   (2.14) 
𝑡𝑠 = 𝑟2, (2.15) 
the scaling of each variable and parameter is shown below. 
?̅?1 =
𝑥1
𝐸0
, ?̅?2 =
𝑥2
𝐸0
, ?̅?3 =
𝑥3
𝐼𝐿0
, 𝜏 = 𝑡𝑠𝑡, 𝑐̅ =
𝑐𝑇0
𝑡𝑠𝐸0
, ?̅? =
𝑎𝐸0
𝑡𝑠𝑇0
, 
?̅?1 =
𝑝1
𝑡𝑠
, ?̅?2 =
𝑝2𝐸0
𝑡𝑠𝐼𝐿0
, ?̅?1 =
𝑔1
𝐼𝐿0
, ?̅?2 =
𝑔2
𝑇0
, ?̅?3 =
𝑔3
𝑇0
, ?̅? = 𝑏𝑇0, 
?̅?2 =
𝜇2
𝑡𝑠
, ?̅?3 =
𝜇3
𝑡𝑠
, ?̅?2 =
𝑟2
𝑡𝑠
, ?̅?1 =
𝑢1
𝑡𝑠𝐸0
, ?̅?2 =
𝑢2
𝑡𝑠𝑇0
, ?̅?3 =
𝑢3
𝑡𝑠𝐼𝐿0
. 
 (2.16) 
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The corresponding state model after Non-dimensional scaling gives the following 
equations. 
𝑑?̅?1
𝑑𝜏
= 𝑐̅?̅?2 − ?̅?2?̅?1 +
?̅?1?̅?1?̅?3
?̅?1 + ?̅?3
+ ?̅?1 (2.17) 
𝑑?̅?2
𝑑𝜏
= ?̅?2?̅?2(1 − ?̅??̅?2) −
?̅??̅?1?̅?2
?̅?2 + ?̅?2
(2.18) 
𝑑?̅?3
𝑑𝜏
=
?̅?2?̅?1?̅?2
?̅?3 + ?̅?2
− ?̅?3?̅?1 + ?̅?2 (2.19) 
In this thesis, all scaled parameters and variables are marked by hats except for scaled 
time 𝜏. 
2.3  Bifurcation and Dynamic Analysis for Non-Treatment Case 
This section revises Kirschner’s work in the nonlinear dynamics analysis of the 
tumor-immune system without control (non-treatment case), equation (2.20) – (2.22). 
Understanding the mathematical dynamics and the corresponding immunological 
implication of the KP model is a vital prerequisite of the thesis research.  
𝑑𝑥1
𝑑𝑡
= 𝑐𝑥2 − 𝜇2𝑥1 +
𝑝1𝑥1𝑥3
𝑔1 + 𝑥3
(2.20) 
𝑑𝑥2
𝑑𝑡
= 𝑟2𝑥2(1 − 𝑏𝑥2) −
𝑎𝑥1𝑥2
𝑔2 + 𝑥2
(2.21) 
𝑑𝑥3
𝑑𝑡
=
𝑝2𝑥1𝑥2
𝑔3 + 𝑥2
− 𝜇3𝑥3 (2.22) 
Although the nonlinear system is difficult to solve analytically, numerical 
methods can be employed to gain an understanding of the dynamics of the tumor-immune 
system. This research uses AUTO (07p) for the bifurcation analysis along with parameter 
c, the antigenicity, and MATLAB for the temporal dynamical simulation at fixed c. 
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AUTO [32][33][34] is a powerful continuation and bifurcation analysis software for 
differential equations. Given an initial state near equilibrium branches, AUTO can 
automatically approach an equilibrium point, and numerically analyze the stability of 
either equilibriums or limit cycles, then continue the branches point by point.  
The combined usage of bifurcation analysis and simulation helps to reveal the 
non-local dynamics of the model, and it goes as following way. The bifurcation analysis 
along the antigenicity c predicts the non-local dynamical trends of the states at each fixed 
c, which also guide the selection of the initial states in simulation. In turn, simulations in 
Matlab serve as initial conditions for the numerical calculation in AUTO. AUTO is able 
to do the continuation of solutions of ODEs based on the appropriate initial guess of 
equilibrium points. Simulations are also supplements for several situations that AUTO is 
unable to solve, such as chaos, though not found in this research.  
2.3.1 Bifurcation Diagram and Simulation Results 
Human immune systems have multiple defense mechanisms in the face of 
external invasions or internal abnormal variations. Different than external invader such as 
virus, the tumor is one of the internal abnormal variations. Making out those tumor cells 
is the precondition for a successful self-immune defense. Furthermore, different levels of 
the identifying capability of immune systems activate different defense mechanisms. In 
other words, human immune responses vary with the antigenicity of effector cells.  
Bifurcation analysis, especially bifurcation diagram, of the KP model shows the 
diversity of tumor-immune response. To be specific, the nonlinear dynamics of non-
treatment model changes qualitatively along with parameter c. As shown in Figure 2.4, 
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the nonlinear dynamics of the non-dimensional tumor population presents a “foot-like” 
bifurcation structure along with the antigenicity 𝑐 between [−0.01, 0.05].  
Note that this research studies the non-local dynamics of the system within the 
nonnegative state space as the negative state is meaningless in neither the natural immune 
response nor the clinical immunotherapy. For the antigenicity, though the area with 
negative values, 𝑐 ∈ [−0.01,0), is insignificant in practice, it shows the bifurcation 
structure of the tumor evolution.  
There are two bifurcation branches are captured. One branch is a lateral straight 
line representing an unstable equilibrium point at origin independent of 𝑐, which can be 
easily captured by solving the state model with all zero states. Figure 2.4 shows the other 
bifurcation branch. The “foot-like” bifurcation branch changes dramatically with 𝑐. 
Consider the nonnegative 𝑐 part of the bifurcation diagram, two bifurcations points 𝑐0 
and 𝑐1 separate the graph into three rectangular areas with distinct nonlinear dynamical 
patterns. AUTO shows that 𝑐0 is a fold, and 𝑐1 is a Hopf bifurcation. Figure 2.5 zooms in 
on the surrounding area of 𝑐0. It shows that the exact type of bifurcation point 𝑐0 is not 
clear. It is either a saddle-node bifurcation or a homoclinic bifurcation depends on 
whether the saddle point collides with the limit cycle branch or not. Auto shows that the 
limit cycle branch is approaching to 𝑐0 but not touch it. Further analysis is necessary for 
the judgment. However, this uncertainty would not affect the understanding of the system 
dynamics and the following researches. 
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Figure 2.4 Bifurcation diagram of the non-treatment KP model 
 
Figure 2.5 Bifurcation diagram of the non-treatment KP model in the neighborhood of 𝒄𝟎 
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Figure 2.6 Bifurcation diagram of the non-treatment KP model in semi-logarithmic 
coordinates 
Next, the dynamics of the non-treatment KP model within each c area is simulated 
by Matlab with a uniform initial condition that ?̅?(0) = [1 × 10−4, 1 × 10−4, 1 × 10−4]𝑇. 
Note that all simulations for the tumor-immune dynamics based on any model in this 
thesis employ this initial condition unless otherwise stated, which is corresponding to the 
number of cells and the concentration of IL-2 at a level of 105.  
Firstly, discuss the dynamics shown in the “foot-like” branch in detail. Consider 
the rectangular parts, in Part I (“heel area”) where c ranges from 0 to 𝑐0 = 8.55 × 10
−5, a 
stable equilibrium point with large tumor population coexists with two unstable 
equilibrium points. As shown in Figure 2.5, the stable stationary branch collides with the 
upper unstable branch at bifurcation 𝑐0. Within Part I, the population of tumor cells 
would either boom up monotonously or shrink slightly to the stable steady state based on 
the initial condition. Figure 2.7 shows the temporal dynamics of effector cells, tumor 
cells and IL-2 at 𝑐 = 1 × 10−5. 
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Figure 2.7 Dynamics of non-treatment KP Model at 𝒄 = 𝟏 × 𝟏𝟎−𝟓 
In Part II (“instep area”) where c ranges from 𝑐0 to 𝑐1 = 0.0326, a branch of 
unstable equilibrium points and a branch of stable periodic orbits are discovered. Figure 
2.6 presents the bifurcation diagram in a semi-logarithmic coordinate system to show the 
unclear periodic part before 𝑐1 in Figure 2.4. As displayed in Figure 2.8, the tumor 
population converge to a periodic orbit regardless of the initial conditions under the 
immunological surveillance. In a single period, the tumor stays at a dormant status that 
only few cells persist for most of the time. During the dormant status, the tumor 
population is probably too small to discover. However, the population of tumor bursts 
suddenly implying the recurrence of tumor, which is extremely common in clinics. 
Within Part II, the immune response behaves more intense as the antigenicity of effector 
cells enhances. The periodic orbit shrinks as well as the recurrence period. Table 2.2 
compares the periodic tumor dynamics at 𝑐 = 0.02 and 𝑐 = 0.03 with the same initial 
condition in terms of the maximum value, the amplitude of periodic orbits and the 
recurrence period. Both the maximum tumor population in general and in period status 
decline as 𝑐 increases, and the recurrence period shortens.  
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c 
Non-dimensional tumor dynamics Dimensional tumor dynamics 
Maximum 
value 
Periodic 
amplitude 
Period 
Maximum 
value 
Periodic 
amplitude 
Period 
0.02 3.7 × 10−4 3.7 × 10−4 43.6 3.7 × 105 cells 3.7 × 105 cells 242days 
0.03 1.3 × 10−4 6.9 × 10−5 19.3 1.3 × 105 cells 6.9 × 104 cells 107days 
Table 2.2 Comparison of the periodic tumor dynamics at 𝒄 = 𝟎. 𝟎𝟐 and 𝒄 = 𝟎. 𝟎𝟑 
 
 
Figure 2.8 Dynamics of non-treatment KP Model at 𝒄 = 𝟎. 𝟎𝟐 and 𝒄 = 𝟎. 𝟎𝟑 
In Part III (“toe area”), Hopf bifurcation occurs at 𝑐1, where the stable branch of 
limit cycles bifurcates from the stable equilibrium branch. There is a unique stable focus 
with rather small value in Part III. This area refers to a “safe” tumor status that the tumor 
population keeps small and harmless to the host. Figure 2.9 shows that the tumor 
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population converges oscillatorily to a stable status. Table 2.3 compares the tumor 
dynamics with 𝑐 = 0.035 and 𝑐 = 0.04, in terms of the second peak value, the steady 
state and the converge time. The tumor population converges faster and reaches a lower 
stable amount with a higher value of 𝑐. 
c  
Non-dimensional value Dimensional value 
2nd peak value Steady state 
Converge 
time 
2nd peak 
value 
Steady state 
Converge 
time 
0.035 9.8 × 10−5 1.8 × 10−5 ~700 9.8 × 104 1.8 × 104 ~10.7years 
0.04 7.8 × 10−5 1.6 × 10−5 ~300 7.8 × 104 1.6 × 104 ~4.6years 
Table 2.3 Comparison of the periodic tumor dynamics at 𝒄 = 𝟎. 𝟎𝟑𝟓 and 𝒄 = 𝟎. 𝟎𝟒 
 
 
Figure 2.9 Dynamics of non-treatment KP Model at 𝒄 = 𝟎. 𝟎𝟑𝟓 and 𝒄 = 𝟎. 𝟎𝟒 
  
23 
CHAPTER THREE  CONTROL OF IMMUNOTHERAPIES 
This chapter applies and analyzes several control strategies on the 
immunotherapies based on the KP model in order to eradicate tumors or inhibit tumor 
growths. Specifically, an open-loop control constructs an ideal stable equilibrium point at 
tumor-free state. This local tumor-free equilibrium point indicates that regular 
quantitative immunotherapy could cure the tumor whose initial condition is not far from 
the stable equilibrium point. While the stability of this local tumor-free equilibrium point 
is independent of 𝑐, it is observed that the range of the stability depends on the 
antigenicity. Furthermore, this research also attempts to modify the tumor-immune 
interactions via bifurcation control with washout filters based on the bifurcation structure 
of the system itself. The bifurcation control aims to extend the “safe” equilibrium branch 
area and reduce the amplitude of the periodic orbits discovered by the KP model and 
discussed in the last chapter. 
3.1  Open-Loop Control and Dynamic Analysis 
This section studies the dynamics of the tumor-immune response with open-loop 
control. Constant control input 𝑢1 and 𝑢2 implies regular quantitative implantation of 
ACI and IL-2, respectively. This open-loop control aims to construct an asymptotically 
stable equilibrium point at the tumor-free state, i.e., an equilibrium point  
𝒙𝒔𝒔 = (𝑥1
∗, 0, 𝑥3
∗) (3.1) 
with positive constant 𝑥1
∗ and 𝑥3
∗. The equilibrium point at the origin of the KP model 
without treatment, i.e., the all-zero state independent of 𝑐, naturally generates the open-
loop control idea.  All-zero state implicates that there are no effector cells, IL-2 and 
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tumor cells in a living host. This status is neither possible nor desired. Although the 
unstable all-zero equilibrium point makes no sense in an immune system, it raises the 
question if it is possible to construct a stable equilibrium point with a zero 𝑥2 state, 
representing the tumor-free status with bounded effector cells and IL-2. The simplest 
solution for constructing such an equilibrium point is by applying constant feedforward 
control.This part first revises Kirschner and Panetta’s work [15] on the condition of 
applying ACI and IL-2 that can eliminate tumors in the open-loop control system. The 
thesis analyzed the open-loop system from the perspective of control designing, while 
they focus on comparing the treatment effects of various immunotherapies and guiding 
their dosage. Furthermore, the thesis applies a specific treatment combining ACI and IL-
2, which raises the problem of estimating the region of attraction of the tumor-free state. 
Several attempts have been conducted on the estimation.  
Based on the most general KP model, equation (2.4)-(2.5), add constants 
feedforward control inputs 𝑠1 and 𝑠2 into the first and third equations respectively in 
order to move the equilibrium point from origin to the desired tumor-free status. The state 
model of the open-loop control system 
?̇? = 𝒇𝒐(𝒙) (3.2) 
turns to be 
𝑑𝑥1
𝑑𝑡
= 𝑐𝑥2 − 𝜇2𝑥1 +
𝑝1𝑥1𝑥3
𝑔1 + 𝑥3
+ 𝑠1 (3.3) 
𝑑𝑥2
𝑑𝑡
= 𝑟2𝑥2(1 − 𝑏𝑥2) −
𝑎𝑥1𝑥2
𝑔2 + 𝑥2
(3.4) 
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𝑑𝑥3
𝑑𝑡
=
𝑝2𝑥1𝑥2
𝑔3 + 𝑥2
− 𝜇3𝑥3 + 𝑠2, (3.5) 
where 𝑠1 and 𝑠2 are positive scalars. Solve the new equilibrium point via  
?̇?𝒔𝒔 = 𝒇𝒐(𝒙𝒔𝒔) = 𝟎. (3.6) 
The desired tumor-free equilibrium point in terms of 𝑠1 and 𝑠2 is  
𝒙𝒔𝒔 = (𝑥1
∗, 0, 𝑥3
∗) = (
𝜇3𝑔1𝑠1 + 𝑠1𝑠2
𝜇2𝜇3𝑔1 + (𝜇2 − 𝑝1)𝑠2
, 0,
𝑠2
𝜇3
) . (3.7) 
Judge the stability of 𝒙𝒔𝒔 by linearization. The Jacobian matrix  
𝐽𝑜 =
𝜕𝒇𝒐(𝒙)
𝜕𝒙
|
(𝒙=𝒙𝒔𝒔)
(3.8) 
becomes  
[
 
 
 
 
 
 −𝜇2 +
𝑝1𝑥3
∗
𝑔1 + 𝑥3∗
𝑐
𝑝1𝑔1𝑥1
∗
(𝑔1 + 𝑥3∗)2
0 𝑟2 −
𝑎𝑥1
∗
𝑔2
0
0
𝑝2𝑥1
∗
𝑔3
−𝜇3 ]
 
 
 
 
 
 
. (3.9) 
The eigenvalues of the system are 
−𝜇2 +
𝑝1𝑥3
∗
𝑔1 + 𝑥3∗
, 𝑟2 −
𝑎𝑥1
∗
𝑔2
, −𝜇3. (3.10) 
The equilibrium point of the nonlinear system is locally asymptotically stable if 
all the eigenvalues of its Jacobian matrix are positive. Then, the equilibrium point 𝒙𝒔𝒔 is 
locally asymptotically stable if 𝑠1 and 𝑠2 satisfy that 
𝑠2 <
𝜇2𝜇3𝑔1
𝑝1−𝜇2
≜ 𝑠𝑢𝑝𝑝𝑒𝑟
2 , 𝑠1 >
𝑔2𝑟2
𝑎
[
𝑔2(𝜇2 − 𝑝1) + 𝜇2𝜇3𝑔1
𝜇3𝑔1 + 𝑠2
] ≜ 𝑠𝑙𝑜𝑤𝑒𝑟
1 . (3.11) 
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𝑠𝑢𝑝𝑝𝑒𝑟
2  and 𝑠𝑙𝑜𝑤𝑒𝑟
1  are defined as the upper bound of 𝑠2 and the lower bound of 𝑠1 
respectively. 𝑠𝑢𝑝𝑝𝑒𝑟
2  is a constant while 𝑠𝑙𝑜𝑤𝑒𝑟
1  is a function of  𝑠2. Now consider the 
range of 𝑠1 and 𝑠2 before scaling, in which case all parameters employed are unscaled. 
Figure 3.1 shows the function of 𝑠𝑙𝑜𝑤𝑒𝑟
1 (𝑠2) with 𝑠2 below 𝑠𝑢𝑝𝑝𝑒𝑟
2 = 6.349 × 107. The 
area I refers to the range of 𝑠1 and 𝑠2 that 𝒙𝒔𝒔  is asymptotically stable in local.  
 
 
Figure 3.1  𝒔𝟐 − 𝒔𝒍𝒐𝒘𝒆𝒓
𝟏  curve 
Since both 𝑠1 and 𝑠2 are external resources, a combination of 𝑠1 and 𝑠2 of lower 
amount might be better for both the feasibility and safety of immunotherapy. As a result, 
the following research studies the dynamics of 𝑠1 = 𝑠2 = 1 × 10
3. 
This specific open-loop treatment results in a locally asymptotically stable 
equilibrium point at 𝒙𝒔𝒔
𝟎 = (3.334 × 104, 0, 100) or ?̅?𝒔𝒔
𝟎 = (3.334 × 10−5, 0,1 × 10−7 ) 
independent of 𝑐. As shown in Figure 3.2, the population of tumor cells damps rapidly 
with the initial condition 𝒙(0) = [1 × 10−4, 1 × 10−4 ,1 × 10−4]𝑇 c. However, the 
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region of attraction (ROA) of the locally asymptotically stable equilibrium point varies 
with 𝑐. As shown in Figure 3.3, the point ?̅? = [1 × 10−4, 5 × 10−4, 1 × 10−4]𝑇 is outside 
the ROA when 𝑐 = 1 × 10−5 and inside the ROA when 𝑐 = 0.02. 
 
(a) 𝒄 = 𝟏 × 𝟏𝟎−𝟓                                                         (b) 𝒄 = 𝟎. 𝟎𝟓  
Figure 3.2  dynamics of the open-loop KP model with ?̅?𝟐𝟎 = 𝟏 × 𝟏𝟎
−𝟒 
 
(a) 𝒄 = 𝟏 × 𝟏𝟎−𝟓                                                         (b) 𝒄 = 𝟎. 𝟎𝟐  
Figure 3.3  dynamics of the open-loop KP model with ?̅?𝟐𝟎 = 𝟓 × 𝟏𝟎
−𝟒 
In this thesis research, simulation results of various initial conditions and 
parameter 𝑐 show that the ROA set expands as 𝑐 increases although the exact boundary of 
the ROA is still not clear. The ROA of the tumor-free equilibrium point refers to a three 
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dimensional open, connected, invariant set according to the Lemma 8.1 in  [13]. The 
ROA set is bounded by trajectories of the system. As a result, simulations of the 
dynamics with multiple initial states and antigenicity values could give the exact 
boundary of ROA in theory. Lyapunov analysis is another option to approach a 
conservative ROA, but an appropriate Lyapunov function is necessary.  
In summary, the open-loop control represents the regular quantitative injection of 
both ACI and IL-2. Within the stabilizable set of 𝑠1 and 𝑠2, this treatment constructs a 
tumor-free steady state which is locally asymptotically stable. While the value of the 
steady state is independent of the antigenicity, simulation results show that its region of 
attraction depends on the antigenicity. This ROA is a three dimensional open, connected 
and invariant set. In general, it is observed that the ROA extends as the antigenicity 
enhances. The exact ROA is not clear now. The work of finding the quantitative 
relationship between the antigenicity and the ROA has been left to the future. 
3.2  Bifurcation Control with Washout Filters 
This section applies bifurcation and amplitude control strategies on the tumor-
immune system. These control approaches modify the bifurcation structures in the system 
to achieve desired results. Different than linear systems, the dynamics of nonlinear 
systems is rich and complex, often exhibiting nonlinear phenomena such as bifurcations 
and chaos. Bifurcation control with washout filter could adjust the behavior of a system 
by taking advantages of the original structure rather than destroy it. In this case, the 
bifurcation diagram gives the specific “foot-like” non-local structure of the nominal 
system along parameter 𝑐, based on the bifurcation analysis. The “toes” part, Part III with 
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𝑐 larger than 𝑐1 ( the Hopf bifurcation point), represents a benign condition of the tumor-
immune system. It is beneficial if any treatment could enlarge this field. In the middle 
part of the bifurcation diagram, the amplitude of the periodic orbits increases sharply as 𝑐 
decrease. It is also beneficial if any treatment could reduce the amplitude of the periodic 
orbits. 
3.2.1  Preliminaries of Bifurcation Control 
Bifurcation Control with Washout Filter is dynamic feedback control. Washout 
filter is a stable high pass filter with a property of equilibrium preservation. Washout 
filter rejects steady-state input signals when transient inputs pass through the system. As 
a result, control with washout filters would not impact the open-loop equilibriums of the 
original system.  
Washout filters are widely used in aircraft control systems [37] and power control 
systems [38]. The transfer function of washout filter takes the form 
𝐺(𝑠) =
𝑦(𝑠)
𝑥(𝑠)
=
𝑠
𝑠 + 𝑑
= 1 −
𝑑
𝑠 + 𝑑
. (3.12) 
Here d is a positive constant, which corresponds to utilizing stable washout filters. 
Consider a 𝑛-dimensional state model ?̇? = 𝒇(𝒙) (𝑥 ∈ ℝ𝑛) with steady state 𝒙𝒔𝒔. For each 
state 𝑥𝑖, introduce a washout filter state 𝑧𝑖, and let its transfer function to be 
𝑧𝑖(𝑠) =
1
𝑠 + 𝑑
𝑥𝑖(𝑠). (3.13) 
The dynamic equation of the washout filter is in forms of 
?̇?𝑖 = 𝑥𝑖 − 𝑑𝑧𝑖 (3.14) 
with the output equation 
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𝑦𝑖 = 𝑥𝑖 − 𝑑𝑧𝑖. (3.15) 
The steady state of 𝒛 is 𝒛𝒔𝒔 =
𝒙𝒔𝒔
𝑑
, and the output of the washout filter y = 0 at the steady 
state. It is simple to see that the equilibrium of systems would not change when applying 
a control input in the form 
𝑢 = ℎ(𝑦) (3.16) 
such that  
ℎ(0) = 0. (3.17) 
Wang and Abed [27] incorporate washout filters into bifurcation and chaos 
control. The previous analysis explains the principle why a dynamic feedback control 
with washout filters would not change the equilibrium structure of a system from the 
perspective of exact state models. Furthermore, the property to preserve equilibriums of 
washout filters exists regardless of any model uncertainty that does not violate the finite 
dimensionality of the system. This capability under model uncertainty is beneficial 
greatly to the biological system since there exist large ranges of nonlinear model 
uncertainties due to individual differences among livings.  
This thesis aims to move the Hopf bifurcation point 𝑐1 in the KP model. 
Considers the system (2.2), there are pairs of purely imaginary eigenvalues when Hopf 
bifurcations take place. At the critical points, the linearization method (eigenvalues of the 
Jacobian matrix) does not work for judging the stability. Periodic limit cycles 𝑝𝜖 are 
bifurcated from Hopf bifurcations when c is perturbed by 𝜖, the asymptotical stability of 
𝑝𝜖 is determined by the characteristic exponent 𝛽(𝜖), which is defined by a real, smooth, 
even function that  
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𝛽(𝜖) = 𝛽2𝜖
2 + 𝛽4𝜖
4 + ⋯ . (3.18) 
𝑝𝜖 is orbitally asymptotically stable if 𝛽(𝜖) < 0 and is unstable if 𝛽(𝜖) > 0. Typically, 
the sign of the characteristic exponent 𝛽(𝜖) depends on the sign of 𝛽2, which is called the 
bifurcation stability coefficient [39][36]. It is known that only the linear, quadratic and 
cubic terms possess the potential to influence the value of 𝛽2 for a system undergoing 
Hopf bifurcations (or Andronov-Hopf bifurcations) [39][40][41][42]. Let the bifurcation 
control 𝑢 consists of linear, quadratic and cubic terms in the form of 
𝑢 = 𝑘𝑙𝑦 + 𝑦
𝑇𝑄𝑢𝑦 + 𝐶𝑢(𝑦, 𝑦, 𝑦), (3.19) 
where y is the vector of washout filter outputs 𝑦𝑖 = 𝑥𝑖 − 𝑑𝑖𝑧𝑖, 𝑘𝑙 is a real scalar, 𝑄𝑢 is a 
real symmetric 𝑛 × 𝑛 matrix, and 𝐶𝑢 is a cubic form generated by a scalar-valued 
symmetric trilinear form. In the following control application, each term of the 
bifurcation with washout filter are employed and analyzed separately. 
3.2.2 The Bifurcation Control Model with Washout Filters in Tumor-Immune Interactions 
Consider the KP model, introduce dynamic feedback control with washout filters 
into the dynamics of ACI and IL-2. Give the closed-loop tumor-immune system with 
washout filters in a general form 
[?̇?, ?̇?]𝑇 = 𝒇(𝒙, 𝒛, 𝒖), (3.20) 
where 𝒛 = [𝑧1, 𝑧3] is the washout filter state. Here is the state equations of the closed-
loop tumor-immune control system 
𝑑𝑥1
𝑑𝑡
= 𝑐𝑥2 − 𝜇2𝑥1 +
𝑝1𝑥1𝑥3
𝑔1 + 𝑥3
+ 𝑢1 (3.21) 
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𝑑𝑥2
𝑑𝑡
= 𝑟2𝑥2(1 − 𝑏𝑥2) −
𝑎𝑥1𝑥2
𝑔2 + 𝑥2
(3.22) 
𝑑𝑥3
𝑑𝑡
=
𝑝2𝑥1𝑥2
𝑔3 + 𝑥2
− 𝜇3𝑥3 + 𝑢2 (3.23) 
𝑑𝑧1
𝑑𝑡
= 𝑥1 − 𝑑1𝑧1 (3.24) 
𝑑𝑧3
𝑑𝑡
= 𝑥3 − 𝑑3𝑧3 (3.25) 
along with the output equations 
𝑦1 = 𝑥1 − 𝑑1𝑧1 (3.26) 
𝑦2 = 𝑥3 − 𝑑3𝑧3 (3.27) 
𝑦3 = 𝑥2 (3.28) 
where the control inputs are governed by real smooth functions 
𝑢1 = ℎ1(𝑦1) (3.29) 
𝑢2 = ℎ2(𝑦2). (3.30) 
Note that, all the washout filter coefficients 𝑑𝑖 are uniformly set as 0.5 without losing any 
generality. 
3.2.3  Bifurcation Control with Linear Dynamic Feedback 
In this part, we consider the linear dynamic feedback control strategy  
𝑢𝑖 = −𝑘𝑙𝑖𝑦𝑖 , 
where 𝑘𝑙𝑖, so-called linear feedback gain, is a designed scalar. The objective of the linear 
dynamic feedback control is to either extend the region of single “safe” steady state 
captured by the bifurcation diagram of the non-treatment system or shrink the amplitude 
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of tumor recurrences, via moving the Hopf bifurcation that marks the lower boundary of 
the “toe area” to a smaller 𝑐. The influence of this closed-loop treatment is analyzed in 
AUTO. 
1) Adoptive cellular immunotherapy (𝒖𝟏 = −𝒌𝒍𝟏𝒚𝟏, 𝒖𝟐 = 𝟎 ) 
Consider the situation that only adoptive cellular immunotherapy is applied. 𝑘𝑙1 is 
the constant (linear) feedback gain of the washout filter. 𝑘𝑙1 < 0 refers to implanting 
activated anti-tumor effector cells into the patient, while 𝑘𝑙1 > 0 indicates an initiative 
action to reduce the amount of the effector cells. Despite that, to the best of the author’s 
knowledge, there is no immunotherapy treatment aiming to reduce the amount of the 
effector cells, this research could still provide an idea to structurally improve a system 
with complex nonlinear phenomena under modeling uncertainty.  
Routh criterion is commonly used to theoretically analyze the controllable set of 
𝑘𝑙, however, hardly could it be employed here due to the mathematically intricate model. 
Therefore, this research numerically calculates, via AUTO, the Hopf bifurcation of the 
closed-loop control systems with varying values of the feedback gain, in order to find the 
controllable range. According to the previous study, the bifurcation point of the non-
treatment tumor-immune system is at 𝑐1 = 3.26 × 10
−2, and the physically valid range 
of the antigenicity 𝑐 is [0, 0.05]. Figure 3.4 (a) shows the range of 𝑘𝑙1 moving the 
bifurcation points in both directions, that either 𝑐1 increases or decreases, within the 
physically valid range of 𝑐. 𝑐1 moves to left (decrease) under the control of 𝑘𝑙1 ∈
(0, 0.034], and moves to right (increase) under the control of 𝑘𝑙1 ∈ [−0.19, 0) ∪
(0.034, 1.3). Figure 3.4 (b) shows the part that 𝑐1 moves to the left, under which the 
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“safe equilibrium” area extends. This curve shows that the minimum value of 𝑐1 takes 
place within (0.11, 0.16) at 𝑐1 = 3.09 × 10
−2.   
 
(a)                                                                          (b) 
Figure 3.4  𝒌𝒍𝟏 − 𝒄𝟏 curve 
 
The above discussion shows the capability of the linear, dynamic feedback control 
along the state 𝑥1 to place the Hopf bifurcation point of the tumor-immune system to any 
point inside 𝑐1 ∈ [3.09, 0.05] × 10
−2. Figure 3.5 (a) and (b) shows the bifurcation 
diagram, along parameter 𝑐, at 𝑘𝑙1 = 0.013 and 𝑘𝑙1 = −0.018 representing the limit 
movability to left and right, respectively. Compared to Figure 2.6, the bifurcation 
diagram of the non-treatment KP model, Auto shows that the left-side movability of Hopf 
bifurcation is limited, while the right-side movability is strong via linear dynamic 
feedback control with washout filters. 
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(a) 𝒌𝒍𝟏 = 𝟎.𝟎𝟏𝟑 (ultimate movability to left)(b) 𝒌𝒍𝟏 = −𝟎.𝟎𝟏𝟖 (ultimate movability to right) 
Figure 3.5  the bifurcation diagrams of the closed-loop tumor-immune system with linear 
dynamic control along 𝒙𝟏 
 
Besides the movability of Hopf bifurcation, it is shown that the linear dynamic 
feedback control also changes the amplitude and the periods of limit cycles in the “instep 
area”. Consider the KP model with two representative fixed values of the antigenicity, 
𝑐 = 0.02, and 𝑐 = 0.04, presenting Part II (periodic orbits) and Prat III (safe equilibrium) 
of the bifurcation structure of the non-treatment KP model respectively. Figure 3.6 (a) 
and (b) shows the influence of the constant control gain 𝑘l1 to the tumor dynamics. These 
figures compare the tumor involution under the linear dynamic washout control among 
the non-treatment case and two limit-movability cases for the Hopf bifurcation.  
According to the tumor involution, while the range of “safe” single equilibrium 
extends, the amplitude of periodic orbits amplifies at the same time. The increase of the 
amplitude is limited with a limited left-side movability of the linear dynamic feedback 
control. In the other direction, though the bifurcation control with 𝑘𝑙 = −0.18 shrinks the 
region of “safe equilibrium”, it reduces the amplitude of the first tumor explosion and the 
following tumor relapses at lower antigenicity levels. At 𝑐 = 0.02, the control with 𝑘𝑙 =
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−0.18 lead to an around twenty percent reduction in the peak of tumor dynamics, which 
is around 2 × 10−4 after scaling and 2 × 105 cells. In the aspect of the time period, the 
control with 𝑘𝑙 = −0.18 shortens the recurrence period by one third at 𝑐 = 0.02.   
In summary, the linear dynamic feedback control with washout filters is able to 
move the Hopf bifurcation slightly to left and arbitrarily to right. By implanting ACI in 
the designed way, the amplitude of the tumor growth significantly drops at a lower 
antigenicity level. However, this treatment is also at risk of shortening the recurrence 
periods and extending the area where periodic orbits generate.  
 
(a) 𝒄 = 𝟎. 𝟎𝟐                                                         (b) 𝒄 = 𝟎. 𝟎𝟒  
Figure 3.6 The influence of the constant control gain 𝒌𝒍𝟏 to the tumor dynamics of the closed-
loop KP model with linear dynamic control along 𝒙𝟏 
2) Interleukin-2 (𝒖𝟏 = 𝟎, 𝒖𝟐 = −𝒌𝒍𝟐𝒚𝟐) 
A simulation test of linear, dynamic feedback control strategy along 𝑥3 (IL-2) is 
also applied.  However, the numerical analysis of this closed-loop system with 𝑢3 =
−𝑘𝑙3𝑦3 shows no noticeable change in either the tumor dynamics or the bifurcation 
diagram.  
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3.2.4  Amplitude Control with Quadratic or Cubic Dynamic Feedback 
This thesis also studies the effect of amplitude control with quadratic and cubic 
dynamic feedback in ACI and IL-2. There was an expectation that the quadratic or cubic 
dynamic feedback with washout filters could modify the amplitude of the periodic orbits 
in the “instep area”. 
The quadratic dynamic feedback control employs  
𝑢𝑖 = 𝑘𝑞𝑖𝑦𝑖
2 (3.31) 
and the cubic dynamic feedback control employs 
𝑢𝑖 = 𝑘𝑐𝑖𝑦𝑖
3. (3.32) 
where constant 𝑘𝑞𝑖 and constant 𝑘𝑐𝑖 is the quadratic feedback gain and the cubic feedback 
gain, respectively.  
Controllability theories of linear systems do not apply for the linearized nonlinear 
system with dynamic feedback control. The simulation and AUTO results show that there 
is no noticeable change of tumor dynamics with either quadratic or cubic dynamic 
feedback control with washout filters along 𝑥1 and 𝑥3.   
Though the effect of quadratic and cubic dynamic control with washout filters are 
limited in the KP model, it is possible to employ them into other tumor-immune system 
or tumor therapy models that undergo Hopf bifurcations. 
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CHAPTER FOUR  CONCLUSIONS AND FUTURE WORK 
3.1  Conclusions 
This thesis reviews the KP model in bifurcation analysis and part of the open-loop 
treatments with immunotherapies of ACI and IL-2. Based on Kirschner’s works [15] on 
the open-loop control analysis, this thesis also makes an attempt to analyze the region of 
attraction of the open-loop control. Based on the understanding of the tumor-immune 
mechanism explained by the KP model, bifurcation control with washout filters is applied 
to promote the effects of immunotherapies. Different from the open-loop treatment, the 
dynamic feedback with washout filters remains the equilibrium branches of the original 
system. This feature is beneficial to systems under uncertainties, which is a common 
situation in biological models due to individual differences. In the future, the bifurcation 
control with washout filter could be extended into other models of tumor therapies 
undergoing Hopf bifurcations or chaos. 
The classic KP model explains the non-local dynamics of tumor-immune 
interactions involves the effector cells, tumor cells, and IL-2. Two bifurcation branches 
represent the evolution of the tumor population along with the antigenicity. One is a 
single unstable equilibrium point at the origin, which is independent of 𝑐. Within another 
branch, the dynamics of tumor growth changes qualitatively along parameter 𝑐, the 
antigenicity of effector cells. The system possesses a “dangerous” equilibrium close to its 
carrying capacity with a tiny 𝑐. As 𝑐 increases, periodic orbits generate representing the 
neoplasm recurrence. Finally, as 𝑐 passes through the Hopf bifurcation, a “safe” 
equilibrium point appears. 
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It is shown that regular quantitative treatment combing the ACI and IL-2 
constructs a new tumor-free equilibrium point independent of 𝑐. This tumor-free 
equilibrium is locally asymptotically stable. The simulation results show that the region 
of attraction of the tumor-free equilibrium tends to increase as 𝑐 increases. 
It is known that only linear, quadratic and cubic terms are potentially to change 
the stability of a nonlinear system undergoing Hopf bifurcations indirectly via 𝛽2. As a 
result, this thesis applies the linear, quadratic, cubic dynamic feedback control with 
washout filters separately into the KP model. It is shown that a linear dynamic feedback 
treatment with washout filter in ACI is likely to suppress the tumor growth by moving the 
Hopf bifurcation. Qualitatively implanting activated anti-tumor cells flowing the linear 
dynamic control could shrink the amplitude of the tumor recurrences but shorten the time 
periods simultaneously. Simulations and AUTO results indicate that a linear dynamic 
feedback treatment with washout filter in IL-2 presents no noticeable effect, as well as a 
quadratic and cubic dynamic feedback treatments with washout filter in both ACI and IL-
2. 
This thesis attempts to guide the immunotherapies combining ACI and IL-2. The 
behavior of a tumor-immune system highly depends on the antigenicity. A combination 
treatment of ACI and IL-2 have the potentiality to eradicate tumors, but the region of 
attraction turns to reduce as the effector cells become less sensitive to tumor cells. When 
the initial condition is out of the region of attraction, tumor booms up, and this situation 
could be lethal to patients. To avoid this tragedy, implanting the activated anti-tumor 
cells under a bifurcation control with ACI first might be an option when the antigenicity 
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of patients is at a low level. The open-loop treatment could be applied later after that the 
dynamics of the tumor-immune interactions has dropped into the range of action.  
Furthermore, biological systems have individual differences, and it is challenging 
to apply precise measurements in a living system. The bifurcation control with washout 
filters has strength in mitigating the potential negative impact from the modeling 
uncertainties.  
3.2  Future Work 
Further work is needed in the control treatment based on the KP model. Several 
works have been tried to better estimate the region of attraction of the tumor-free 
equilibrium point in the open-loop KP system in section 3.1. Though the results are 
limited, one direction is to find an appropriate Lyapunov function to estimate ROA. It is 
meaningful if the quantitative relationship between the ROA and the antigenicity 𝑐 
becomes clear. 
Bifurcation control, either with or without washout filters, can be good options for 
control applications in tumor treatments and other biological systems. The controlled 
response benefits from remaining the equilibrium structure regardless of model 
uncertainties. This thesis research has also considered and studied a tumor-immune-virus 
system [43] where an equilibrium branch bifurcates to chaos. Control of nonlinear 
phenomena such as bifurcations and chaos in biological systems can be a fruitful research 
area. 
 
 
  
  
41 
BIBLIOGRAPHY 
[1] H. Enderling, M.A. Chaplain. Mathematical modeling of tumor growth and 
treatment. Current Pharmaceutical Design, 20(30): 4934–4940, 2014. 
[2] B. D. Curti, A. C. Ochoa, W. J. Urba, W. G. Alvord, W. C. Kopp, G. Powers, C. 
Hawk, S. P. Creekmore, B. L. Gause, J. E. Janik, J. T. Holmlund, P. Kremers, R. G. 
Fenton, L. Miller, M. Sznol, J. W. Smith II, W. H. Sharfman and D. L. Longo. 
Influence of interleukin-2 regimens on circulating populations of lymphocytes after 
adoptive transfer of anti-CD3-stimulated T cells: Results from a phase I trial in 
cancer patients. Journal of Immunotherapy, 19(4): 296-308, 1996. 
[3] B. L. Gause, M. Sznol, W. C. Kopp, J. E. Janik, J. W. Smith II, R. G. Steis, W. J. 
Urba, W. Sharfman, R. G. Fenton, S. P. Creekmore, J. Holmlund, K. C. Conlon, L. 
A. VanderMolen and D. L. Longo. Phase I study of subcutaneously administered 
interleuking- 2 in combination with interferon alfa-2a in patients with advanced 
cancer. Journal of Clinical Oncology, 14(8): 2234-2241, August 1996. 
[4] I. Hara, H. Hotta, N. Sato, H. Eto, S. Arakawa and S. Kamidono. Rejection of mouse 
renal cell carcinoma elicited by local secretion of interleukin-2. Japanese Journal of 
Cancer Research, 87: 724-729, 1996. 
[5] R. Kaempfer, L. Gerez, H. Farbstein, L. Madar, O. Hirschman, R. Nussinovich and 
A. Shapiro. Prediction of response to treatment in superficial bladder carcinoma 
through pattern of interleukin-2 gene expression. Journal of Clinical Oncology, 
14(6): 1778-1786, June 1996. 
[6] U. Keilholz, C. Scheibenbogen, E. Stoelben, H. D. Saeger and W. Hunstein. 
Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: 
Pattern of progression in responders and patients with stable disease with or without 
resection of residual lesions. European Journal of Cancer, 30A(7): 955-958, 1994. 
[7] Angela J. Lumsden, James P. Codde, Peter H. Van Der Meide and Bruce N. Gray. 
Immunohistochemical characterisation of immunological changes at the tumour site 
after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-c. 
Anticancer Research, 16: 1145Ð1154, 1996. 
[8] F. M. Marincola, D. E. White, A. P. Wise and S. A. Rosenberg. Combination 
therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic 
cancer. Journal of Clinical Oncology, 13(5): 1110-1122, 1996. 
[9] H. Rabinowich, M. Banks, T. E. Reichert, T. F. Logan, J. M. Kirkwood and T. L. 
Whiteside. Expression and activity of signaling molecules n T lymphocytes obtained 
from patients with metastatic melanoma before and after interleukin 2 therapy. 
Clinical Cancer Research, 2: 1263-1274, 1996. 
  
42 
[10]  S. A. Rosenberg, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. 
R. Parkinson, C. A. Seipp, J. H. Einhorn and D. E. White. Treatment of 283 
consecutive patients with metastatic melanoma or renal cell cancer using high-dose 
bolus interleukin 2. JAMA: The Journal of the American Medical Association, 
271(12): 907-913, 1994. 
[11]  M. Rosenstein, S. E. Ettinghousen and S. A. Rosenberg. Extravasion of 
intravascular fluid mediated by the systemic administration of recombinant 
interleukin 2. Journal of Immunology, 137(5): 1735-1742, Sep 1986. 
[12]  D. J. Schwartzentruber. In Vitro predictors of clinical response in patients receiving 
interleukin-2-based immunotherapy. Current Opinion in Oncology, 5: 1055-1058, 
1993. 
[13] H. K. Khalil. Nonlinear systems. Englewood Cliffs, NJ: Prentice-Hall, 1996. 
[14] V. A. Kuznetsov, I. A. Makalkin, M. A. Taylor and A. S. Perelson. Nonlinear 
dynamics of immunogenic tumors: Parameter estimation and global bifurcation 
analysis. Bulletin of Mathematical Biology, 56(2): 295-321, 1994. 
[15] D. Kirschner and J. C. Panetta. Modeling immunotherapy of the tumor-immune 
interaction. Journal of Mathematical Biology, 37: 235-252, 1998. 
[16] C. DeLisi and A. Rescigno. Immune surveillance and neoplasia - I: a minimal 
mathematical model. Bulletin of Mathematical Biology, 39: 201-221, 1977. 
[17] J. A. Adam. Effects of vascularization on lymphocyte/tumor cell dynamics: 
Qualitative features. Mathematical and Computer Modelling, 23(6): 1-10, 1996. 
[18] F. K. Nani and M. N. Oğuztöreli. Modelling and simulation of Rosenberg-type 
adoptive cellular immunotherapy. IMA Journal of Mathematics Applied in Medicine 
& Biology, 11: 107-147, 1994. 
[19] R. J. DeBoer, Pauline Hogeweg, Hub F. J. Dullens, Roel A. DeWeger and Willem 
DenOtter. Macrophage T Lymphocyte interactions in the anti-tumor immune 
response: A mathematical model. The Journal of Immunology, 134(4): 2748-2758, 
April 1985. 
[20] N. Bellomo, L. Preziosi. Modelling and mathematical problems related to tumor 
evolution and its interaction with the immune system. Mathematical and Computer 
Modelling, 32 (34): 413-452, 2000. 
[21]  L.G. de Pillis, Gu W., A. Radunskaya. Mixed immunotherapy and chemotherapy of 
tumors: Modeling, applications and biological interpretations. Journal of Theoretical 
Biology, 238 (4): 841-862, 2006. 
  
43 
[22]  F. A. Rihan, S. Lakshmanan, H. Maurer. Optimal control of tumour-immune model 
with time-delay and immuno-chemotherapy. Applied Mathematics and 
Computation, 353: 147-165, 2019. 
[23]  D.G. Mallet, L.G. De Pillis. A cellular automata model of tumor–immune system 
interactions. Journal of Theoretical Biology, 239 (3): 334-350, 2006. 
[24]  T.L. Chien, C.C. Chen, C.J. Huang. Feedback linearization control and its 
application to MIMO cancer immunotherapy. IEEE Transactions on Control 
Systems Technology, 18(4): 953-961, 2010. 
[25]  S. A. Rosenberg, M. T. Lotze. Cancer immunotherapy using interleukin-2 and 
interleukin-2-activated lymphocytes. Annual Review of Immunology, 4: 681-709, 
1986. 
[26]  E. H. Abed, H. O. Wang, and A. Tesi. Control of bifurcations and chaos. In W. S. 
Levine, editor, The Control Handbook, 951-966. CRC Press & IEEE Press, Boca 
Raton, FL, 1995. 
[27]  H. O. Wang, E. H. Abed. Bifurcation control of a chaotic system. Automatica, 31 
(9): 1213-1226, 1995. 
[28]  McAneney H, O’Rourke SFC. Investigation of various growth mechanisms of solid 
tumour growth within the linear-quadratic model for radiotherapy. Physics in 
Medicine and Biology, 52(4): 1039-54, 2007. 
[29]  Gompertz B. On the nature of the function expressive of the law of human 
mortality, and on a new mode of determining the value of life contingencies. 
Philosophical Transactions of the Royal Society of London, 115: 513-583, 1825. 
[30]  Winsor CP. The Gompertz curve as a growth curve. Proceedings of the National 
Academy of Sciences of the United States of America, 18(1): 1-8, 1932. 
[31]  Prehn RT. The inhibition of tumor growth by tumor mass. Cancer Research, 51(1): 
2-4, 1991. 
[32]  E. J. Doedel. AUTO, a program for the automatic bifurcation analysis of 
autonomous systems. Congressus Numerantium, 30: 265-284, 1981. 
[33]  E. J. Doedel, R. C. Paenroth, A. R. Champneys, T. F. Fairgrieve, Y. A. Kuznetsov, 
B. E. Oldeman, B. Sandstede and X. J. Wang. AUTO2000: Software for 
continuation and bifurcation problems in ordinary differential equations. Technical 
report, California Institute of Technology, Pasadena CA, 2000. 
  
44 
[34]  E. J. Doedel, A. R. Champneys, T. F. Fairgrieve, Y. A. Kuznetsov, B. E. Oldeman, 
R. C. Paenroth, B. Sandstede, X. J. Wang and C. H. Zhang. AUTO-07P: 
Continuation and bifurcation software for ordinary differential equations. Technical 
report, California Institute of Technology, Pasadena CA, 2007. 
[35]  G. Iooss and D. D. Joseph. Elementary stability and bifurcation theory. Springer, 
New York. 1980. 
[36]  D. Chen. Control and anti-control of bifurcations with applications to cardiac 
system and Rayleigh-Benard convection. M.S. Thesis, ECE, Duke University, 1999.  
[37]  B. L. Stevens and F. L. Lewis. Aircraft Control and Simulation. Wiley, New York, 
1992. 
[38]  P. M. Anderson and A. A. Fouad. Power system Control and Stability. Iowa State 
University Press, Ames, IA, 1977. 
[39]  E. H. Abed and J. H. Fu. Local feedback stabilization and bifurcation control: Part I. 
Hopf bifurcation. Systems & Control Letters, 7: 11-17, 1986. 
[40]  J. E. Marsden and M. McCracken. The Hopf Bifurcation and Its Applications. 
Springer-Verlag, New York, 1976. 
[41]  J. H. Fu and E. H. Abed. Families of Lyapunov functions for nonlinear systems in 
critical cases. IEEE Transactions on Automatic Control, AC-38, 3-16, 1993. 
[42]  B. D. Hassard, N. D. Kazarinoff and Y. H. Wan. Theory and Applications of Hopf 
Bifurcation. Cambridge University Press, 1981. 
[43]  R. Eftimie, C. MacNamara, J. Dushoff, J. L. Bramson and D. J. D. Earn. 
Bifurcations and chaotic dynamics in a tumour-immune-virus system. The 
Mathematical Modelling of Natural Phenomena, 11 (5): 65–85, 2016. 
 
 
  
45 
CURRICULUM VITAE 
